ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Alloantibodies"

  • 2019 American Transplant Congress

    Long-Term Outcomes of Eculizumab-Treated Positive Crossmatch Recipients: Allograft Survival, Histologic Findings, and Natural History of the Donor-Specific Antibodies

    C. Schinstock, A. Bentall, S. Byron, L. Cornell, M. Everly, M. Gandhi, M. Stegall

    Mayo Clinic, Rochester, MN

    *Purpose: We aimed to determine long-term outcomes for eculizumab-treated, positive crossmatch (+XM) kidney transplant recipients as compared with +XM and age-matched negative crossmatch (−XM) control…
  • 2019 American Transplant Congress

    Selective CD28 Blockade-Mediated Inhibition of T Follicular Helper Cell and DSA Responses is CTLA-4 Dependent

    G. M. La Muraglia II, M. L. Ford, I. R. Badell

    Emory Transplant Center, Atlanta, GA

    *Purpose: Clinical costimulation blockade of the CD28 pathway in the form of CTLA-4Ig has shown the ability to attenuate T cell dependent DSA responses. However,…
  • 2019 American Transplant Congress

    Long-Term Efficacy and Safety of Everolimus Based Immunosuppression on De Novo Kidney Transplantation with 10 Years Follow-Up

    Y. Watarai1, S. Narumi1, T. Tomosugi1, K. Futamura2, M. Okada1, M. Tsujita2, T. Hiramitsu1, T. Kobayashi3, N. Goto2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 2Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3Kidney Transplantation, Aichi Medical University, Nagoya, Japan

    *Purpose: Long-term efficacy and safety of everolimus (EVR) based immunosuppression for de novo kidney transplant recipient who were involved in A1202 study from our institute…
  • 2019 American Transplant Congress

    Nivolumab-Induced Rejection of a Liver Allograft: PD-1 Inhibition Thwarts Liver Allograft Resistance to Humoral Rejection

    B. T. Lee, H. Han, S. Chopra, A. J. Ahearn

    Surgery, USC Keck School of Medicine, Los Angeles, CA

    *Purpose: Checkpoint inhibitor therapy with Programmed cell death protein (PD-1) inhibitors has recently been FDA approved for the treatment of several malignancies. However, it has…
  • 2019 American Transplant Congress

    Impact Of Delayed Kidney Transplantation On Positive Crossmatch Liver Kidney Transplantation

    Z. Rokop, C. Kubal, B. Ekser, R. Mangus, J. Fridell, P. Mihaylov, W. Goggins

    Department of Surgery, Indiana University Hospital, Indianapolis, IN

    *Purpose: Kidney transplantation in sensitized patients is associated with an increased immunological risk. Significant decrease in circulating anti-HLA donor specific antibodies (DSA) has been observed…
  • 2019 American Transplant Congress

    Memory T Follicular Helper Cell Alloresponse is Memory B Cell Independent and Inhibited by CD28 Costimulation Blockade

    S. Zeng, G. M. La Muraglia II, M. L. Ford, I. R. Badell

    Emory University School of Medicine, Atlanta, GA

    *Purpose: Donor-directed HLA antibodies are an important cause of renal allograft injury, but reliable and durable therapeutic options to prevent or eliminate donor-specific antibodies (DSA)…
  • 2019 American Transplant Congress

    Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation 5 Years Results

    Y. Watarai1, S. Narumi1, T. Tomosugi1, M. Okada1, K. Futamura2, M. Tsujita2, T. Hiramitsu1, T. Kobayashi3, N. Goto2

    1Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 2Transplant Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Japan, 3Kidney Transplant Surgery, Aichi Medical University, Nagoya, Japan

    *Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…
  • 2019 American Transplant Congress

    Immunologic Outcomes In Recipients Of Orthotopic Liver Transplant Induced Only With Steroids

    S. N. Merwat, A. T. Chatila, M. Bilal, R. Kulkarni, H. L. Stevenson, J. H. Fair, S. K. Merwat, T. Kozlowski, M. A. Mujtaba

    The University of Texas Medical Branch, Galveston, TX

    *Purpose: Liver allografts are resistant to antibody mediated rejection (AMR) in the presence of preformed alloantibodies. In most cases donor specific antibodies (DSAs) disappear a…
  • 2019 American Transplant Congress

    NK Cells Are Associated with Alloimmune Failure in Transplanted Children

    E. T. Chambers1, O. Martinez2, M. Robien3, C. Chan1, R. Ettenger4, P. Grimm5, H. Lee1, E. Reed4, L. Stempora6, M. Sarwal7, B. Warshaw8, C. Zhao1, A. D. Kirk6

    1Pediatrics, Duke University, Durham, NC, 2Surgery, Stanford, Palo Alto, CA, 3NIH, Bethesda, MD, 4Pediatrics, UCLA, Los Angeles, CA, 5Pediatrics, Stanford, Stanford, CA, 6Surgery, Duke University, Durham, NC, 7Pediatrics, UCSF, San Francisco, CA, 8Pediatrics, Emory University, Atlanta, GA

    *Purpose: Alloimmune failure, defined as the development of donor specific antibody (DSA) and/ or allograft rejection, remains a significant complication in pediatric kidney transplantation. NK…
  • 2019 American Transplant Congress

    Alloreactive B Cells in Transplant Tolerant Recipients Cannot Differentiate into Antibody-Secreting Cells but Can Suppress Donor-Specific IgG Production By Naïve B Cells

    S. H. Khiew1, J. Chen1, D. Jain1, Q. Wang1, D. Yin1, M. Alegre2, A. S. Chong1

    1Department of Surgery, Section of Transplant, University of Chicago, Chicago, IL, 2Department of Medicine, University of Chicago, Chicago, IL

    *Purpose: Donor specific transplantation tolerance has long been the goal of clinical transplantation. Clinical observations suggest that donor-specific antibodies (DSA) are a major cause of…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 40
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences